Artificial intelligence has already transformed industries such as finance and education, but one of its most important tests may come in medicine: discovering new drugs.
Pharmaceutical giant Pfizer recently signed a licensing agreement with AI biotechnology company Chai Discovery to incorporate generative AI tools into its drug discovery research.
The partnership reflects a wider industry movement toward using AI to help scientists design and evaluate potential treatments more quickly and efficiently.
The agreement gives Pfizer access to Chai Discovery’s AI platform, including its Chai-3 model and a customised system built around Pfizer’s proprietary data and research processes.
The technology focuses on antibody and biomolecule design, allowing AI models to predict and generate molecules with specific biological characteristics.
Traditional drug discovery is a lengthy and costly process. Developing a successful medicine can take more than a decade and billions of dollars, with researchers often testing thousands of compounds before finding promising candidates. Many potential treatments also fail during clinical trials.
AI could improve the early stages of this process by analysing large biological datasets, predicting molecular interactions and generating new designs for scientists to test. By identifying stronger candidates earlier, AI may help reduce wasted experiments and allow researchers to focus on the most promising therapies.
Douglas Williams, a biotech executive with four decades of industry experience, believes AI could significantly influence medicine over the next decade.
“I’ve been in this field for 40 years, and it’s remarkable what some of the young companies I’m involved in are doing with AI,” he said. Williams added that even small improvements in success rates could have a major financial impact because drug development has such a high failure rate.
Chai Discovery’s technology represents an ambitious use of AI because its models aim to create new antibodies from scratch rather than only analyse existing biological structures. However, AI-generated discoveries must still go through traditional laboratory testing to prove they are safe and effective.
Pfizer’s investment does not mean AI has solved drug discovery. Instead, it shows that major pharmaceutical companies increasingly view AI as a valuable research tool. Drug development still requires laboratory studies, animal testing, human trials and regulatory approval.
Experts emphasise that AI will support scientists rather than replace them. Williams noted that human expertise will remain essential because scientific creativity and decision-making cannot be fully automated.
The future of AI in medicine is therefore not simply about replacing human work but expanding what researchers can achieve. As our understanding of biology grows, AI could become one of the most powerful tools available for developing new medicines.
